In August 2017, the results of a Phase II double-blind, placebo controlled clinical trial investigating whether the diabetes drug Exenatide (aka Bydureon) can be repurposed for the treatment of Parkinson’s were published. Despite the fact that the study did not meet most of its end points, the Parkinson’s community got very excited about one … Continue reading An exercise in expectations: Exenatide III
Recent analysis of blood samples collected during the Phase II clinical trial of Exenatide in Parkinson’s has uncovered a very interesting finding that could have major implications for not only Parkinson’s, but for many different neurological conditions. Exenatide is a treatment that helps to control glucose levels in people with diabetes. More recently, however, … Continue reading Exciting Exenatide Exosomes
In a recent post we discussed the results of the Exenatide clinical trial from last year, and looked at some further analysis of the data, which hinted at the possibility that the drug may be having additional benefits (Click here to read that post). The researchers behind the Exenatide study have now published the results … Continue reading Exenatide: Identifying the responders
At 23:30 on the 3rd August 2017, the results of a phase II clinical trial investigating the use of a Glucagon-like peptide-1 receptor (GLP-1R) agonist called Exenatide (Bydureon) in Parkinson’s were published the Lancet journal website. The findings of the study were very interesting. And after years of failed trials, the Parkinson’s community finally had … Continue reading What do you do with a problem like Exenatide?
In my previous post, we briefly reviewed the results of the phase II double-blind, randomised clinical trial of Exenatide in Parkinson’s disease. The study indicates a statistically significant effect on motor symptom scores after being treated with the drug. Over the last few days, there have been many discussions about the results, what they mean … Continue reading Exenatide: An editorial
The title of today’s post is written in jest – my job as a researcher scientist is to find a cure for Parkinson’s disease…which will ultimately make my job redundant! But all joking aside, today was a REALLY good day for the Parkinson’s community. Last night (3rd August) at 23:30, a research report outlining the … Continue reading Exenatide: One step closer to joblessness!
# # # # A class of diabetes drugs called GLP-1 receptor agonists have exhibited neuroprotective properties in models of Parkinson’s, and a Phase IIb clinical trial produced encouraging. This research has led to a number of parties to start investigating new and old GLP-1 receptor agonists for their potential to slow the progression of … Continue reading A rising tide with liraglutide
# # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2022. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles … Continue reading Monthly Research Review – February 2022
# # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s. It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year … Continue reading The road ahead: 2022
# # # # Drug repurposing represents a means of rapidly testing and bring novel therapies to the patient. By testing clinically available drugs – that have well characterised safety records in a particular medical condition – one can determine if a certain biological pathway is playing an influential role in another disease. A good … Continue reading The terazosin pilot study results